U.S. Capital Markets Stock News

NasdaqGS:TLRY
NasdaqGS:TLRYPharmaceuticals

Undervalued Small Caps With Insider Buying Across Regions

In recent days, the U.S. stock market has experienced significant volatility, with major indices like the Nasdaq and S&P 500 rebounding sharply following a softer tone from President Trump on trade tensions with China. This environment of fluctuating market sentiment underscores the potential opportunities within small-cap stocks, particularly those that may be undervalued and are experiencing insider buying. Identifying such stocks requires a keen understanding of market dynamics and...
NasdaqGS:DAKT
NasdaqGS:DAKTElectronic

High Growth US Tech Stocks To Watch In October 2025

As of October 2025, the U.S. stock market has been experiencing significant volatility, with major indices like the Nasdaq and S&P 500 rebounding sharply after recent declines due to geopolitical tensions. This dynamic environment underscores the importance of identifying high-growth tech stocks that can capitalize on evolving market conditions, particularly those demonstrating resilience and innovation in response to global economic shifts.
NasdaqGS:LPLA
NasdaqGS:LPLACapital Markets

3 Stocks Estimated To Be Up To 30.1% Below Intrinsic Value

Amid recent market volatility, the U.S. stock indices have experienced significant fluctuations, with a notable surge following President Trump's softened stance on China. As investors navigate these turbulent times, identifying stocks that are potentially undervalued can present opportunities for those looking to capitalize on discrepancies between market prices and intrinsic values.
NasdaqGM:BRLT
NasdaqGM:BRLTSpecialty Retail

October 2025's Spotlight On Promising Penny Stocks

As the United States market experiences a notable upswing, with major indices like the Nasdaq, S&P 500, and Dow Jones Industrial Average closing higher following positive developments in U.S.-China relations, investors are keenly observing potential opportunities. Penny stocks may be a throwback term, but the opportunities they represent are far from old news. These smaller or newer companies can offer significant growth potential when supported by strong financials and solid fundamentals. In...
NasdaqGS:RELL
NasdaqGS:RELLElectronic

Do Richardson Electronics’ (RELL) Earnings Beat and Dividend Signal Enduring Profit Growth?

Richardson Electronics reported its first quarter 2026 results on October 8, 2025, posting sales of US$54.61 million and net income of US$1.91 million, both higher than the same period last year, and reaffirmed its quarterly dividend of US$0.06 per common share and US$0.054 per Class B share. These results reflect both revenue and earnings growth paired with continued shareholder returns, highlighting stronger profitability and an ongoing commitment to dividends. With the earnings growth...
NasdaqGS:GERN
NasdaqGS:GERNBiotechs

The Bull Case For Geron (GERN) Could Change Following Major Executive Appointments—Is a New Era Ahead?

In October 2025, Geron Corporation announced a series of executive changes, including the departures of Andrew Grethlein, Ph.D., and Jim Ziegler, and the appointments of Ahmed ElNawawi as Chief Commercial Officer, Shanthakumar Tyavanagimatt as Chief Technical Officer, Dawn Schottlandt as SVP of Investor Relations and Corporate Affairs, and Bryan Ridgell as SVP of Portfolio and Project Management and Chief of Staff. These significant leadership transitions reflect the company’s intent to...
NasdaqCM:TVRD
NasdaqCM:TVRDPharmaceuticals

Can Early REVERT Data Shape Tvardi Therapeutics' (TVRD) Path in the Pulmonary Fibrosis Market?

On October 13, 2025, Tvardi Therapeutics held a special call to provide an update on preliminary results from its Phase 2 REVERT trial evaluating a therapy for idiopathic pulmonary fibrosis. This update offers critical insight into the company’s research progress on a disease with limited treatment options and high unmet need. We’ll look at how the release of new clinical trial data frames Tvardi Therapeutics’ investment narrative and clinical development outlook. Rare earth metals are the...
NasdaqGS:GEMI
NasdaqGS:GEMICapital Markets

Assessing Gemini Space Station After 26.7% Drop and Regulatory Headlines in 2025

If you have been eyeing Gemini Space Station stock lately, you are not alone. Investors are weighing their options closely, especially after watching the share price close at $23.45. This level has some asking whether the current dip signals opportunity or deeper problems ahead. The stock has slid by 7.3% over the past week, and the 30-day picture is even rougher, showing a drop of 26.7%. That kind of movement catches attention, and it is no wonder many are trying to decide whether now might...
NasdaqCM:ATYR
NasdaqCM:ATYRBiotechs

Should You Reconsider aTyr Pharma After the Recent 17% Price Surge?

Deciding what to do with aTyr Pharma stock right now? You’re definitely not alone. With wild price swings in the rearview mirror, investors are wondering if this is a turnaround story or a value trap in disguise. Over the past week, shares actually jumped by 17.1%, shaking off at least some of the sting from a dramatic slide in the last month, where the stock plunged 84.0%. Year-to-date returns remain deep in the red at -75.3%, and those losses stretch even further if you zoom out: down 56.9%...